Van Loon G R
J Clin Endocrinol Metab. 1979 May;48(5):784-9. doi: 10.1210/jcem-48-5-784.
Plasma dopamine, norepinephrine, and epinephrine responses to bromocriptine (2.5 mg orally) or to LRH (100 microgram iv) were studied in seven acromegalic patients. In contrast to normal men, in whom plasma concentrations of catecholamines decrease markedly, acromegalic subjects fail to show decreases in plasma dopamine, norepinephrine, or epinephrine in response to bromocriptine (four of four studied) or LRH (three of four studied). Mean basal plasma catecholamine concentrations do not differ in acromegalic patients, normal men, and a group of nonacromegalic endocrine control patients. Since it appears that bromocriptine and LRH suppress plasma catecholamine concentrations through mechanisms at brain catecholamine neurons, these data are compatible with disordered catecholamine neurons in the brain of patients with acromegaly.
在7例肢端肥大症患者中研究了血浆多巴胺、去甲肾上腺素和肾上腺素对溴隐亭（口服2.5毫克）或促黄体生成素释放激素（静脉注射100微克）的反应。与正常男性不同，正常男性血浆儿茶酚胺浓度会显著降低，而肢端肥大症患者在服用溴隐亭（4例研究对象中的4例）或促黄体生成素释放激素（4例研究对象中的3例）后，血浆多巴胺、去甲肾上腺素或肾上腺素并未降低。肢端肥大症患者、正常男性和一组非肢端肥大症内分泌对照患者的平均基础血浆儿茶酚胺浓度并无差异。由于溴隐亭和促黄体生成素释放激素似乎是通过作用于脑内儿茶酚胺神经元的机制来抑制血浆儿茶酚胺浓度的，因此这些数据与肢端肥大症患者脑内儿茶酚胺神经元紊乱相符。
